Director Joseph Zakrzewski resigns from Sangamo Board effective March 1, 2022

SANGAMO THERAPEUTICS, INC

Joseph S. Zakrzewski voluntarily resigned from the Board, effective March 1, 2022.
Resignation not due to any disagreement with the Company on operations, policies, or practices.
No replacement announced; Board size and composition will adjust upon his departure.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Joseph S. Zakrzewski

Director

SGMO · SANGAMO THERAPEUTICS, INC

Effective: 2022-03-01
Filed: November 22, 2021, 6:59 PM ET

On November 17, 2021, Joseph S. Zakrzewski, a member of the Board of Directors (the “Board”) of Sangamo Therapeutics, Inc. (the “Company”), notified the Company of his voluntary resignation from the Board effective March 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Joseph S. Zakrzewski resigned as Director at SANGAMO THERAPEUTICS, INC.

Action: resigned
Role: Director

Exact text from the filing

On November 17, 2021, Joseph S. Zakrzewski, a member of the Board of Directors (the “Board”) of Sangamo Therapeutics, Inc. (the “Company”), notified the Company of his voluntary resignation from the Board effective March 1, 2022.

View on SEC.gov

SANGAMO THERAPEUTICS, INC filing history →

Source: SEC EDGAR

accession 0001628280-21-023921

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.